Real-world data modeling to evaluate cilta-cel in second vs third-line for refractory myeloma

Download video

37 views

2 months ago

Real-world data modeling to evaluate cilta-cel in second vs third-line for refractory myeloma

$Real-world data modeling to evaluate cilta-cel in second vs third-line for refractory myeloma$

3:08

by VJHemOnc – Video Journal of Hematology \& HemOnc

55:08

Real-World CAR-T Data Update

by HealthTree Foundation for Multiple Myeloma

2:45

Myeloma: real-world data

by VJHemOnc – Video Journal of Hematology \& HemOnc

1:33

Teclistamab for multiple myeloma in US hospitals: real-world data analysis

by VJHemOnc – Video Journal of Hematology \& HemOnc

43:25

by Welsh Value in Health Centre

1:55:15

Lecture 8. Entity Relationship Models (Data Modelling and Databases 2022)

by DS3Lab (ETH Zurich)

52:28

Updates on CAR-T and BCMA Antibodies in Multiple Myeloma

by PeerView Oncology

33:36

Challenged with Multiple EHRs? Reusable Data Models to the Rescue

by Practical Data Solutions (PDS) Healthcare Analytics

$Real-world outcomes of teclistamab for R\/R multiple myeloma$

1:43

Real-world outcomes of teclistamab for R\/R multiple myeloma

by VJHemOnc – Video Journal of Hematology \& HemOnc

37:17

Capture your business needs with conceptual data modelling

by Datavault

2:58

by Data with Zach